News
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...
According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...
8d
GlobalData on MSNSanofi concludes Blueprint Medicines acquisitionSanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...
The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...
Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...
Paris: Sanofi has announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company ...
Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...
6d
Pharmaceutical Technology on MSNSanofi to acquire Vicebio’s share capital for $1.15bn upfrontSanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.
Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...
Hosted on MSN1mon
Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSNPharmaceutical companies have shied away from larger deals in recent years, with the biggest so far in 2025 being Johnson & Johnson’s acquisition of Intra-Cellular Therapies for $14.6 billion.
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results